Kyverna Therapeutics
19 articles with Kyverna Therapeutics
-
BioSpace spoke with several leaders to gather their thoughts and predictions for the new year. Here is the first installment of this two-part series.
-
Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis
11/11/2022
Kyverna Therapeutics today announced the clearance of its first Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of KYV-101, a novel therapy for the treatment of lupus nephritis.
-
Kyverna Therapeutics filed its first IND application this week to test the efficacy and tolerability of KYV-101, a CAR-T therapy for lupus nephritis.
-
Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis
10/18/2022
Kyverna Therapeutics today announced the filing of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for KYV-101, a novel therapy for the treatment of lupus nephritis.
-
Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer
10/13/2022
Kyverna Therapeutics ("Kyverna"), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of Peter K. Maag, Ph.D., as the company's chief executive officer (CEO).
-
This week's Movers & Shakers includes Tessa and Adial bringing in new CEOs, while other companies strengthened their regulatory and medical teams with key appointments
-
Kyverna Therapeutics Names Cell Therapy Expert Tom Van Blarcom, Ph.D., as Senior Vice President, Head of Research
8/23/2022
Kyverna Therapeutics today announced the appointment of Tom Van Blarcom, Ph.D., as Senior Vice President and Head of Research.
-
Kyverna Therapeutics Names Georg Schett, M.D., and Peter A. Merkel, M.D., MPH, to Scientific Advisory Board
8/23/2022
Kyverna Therapeutics today announced the appointment of Georg Schett, M.D. and Peter A. Merkel, M.D. as Scientific Advisors.
-
In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.
-
Together, Intellia and ONK hope to develop, engineer and test new allogeneic CRISPR-edited NK cell therapies.
-
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
1/26/2022
Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures.
-
The amount will be used to enhance research and development efforts for KYV-101 that has a strong potential to treat different types of autoimmune illnesses.
-
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
1/5/2022
Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases.
-
Intellia and Kyverna announced an exclusive agreement to develop and later commercialize an allogeneic CD19 CAR T-cell therapy to treat a wide range of B cell-mediated autoimmune illnesses.
-
Kyverna Therapeutics Announces Exclusive Worldwide Licenses With National Institutes of Health for Autologous and Allogeneic Anti-CD19 CAR T Cellular Therapies to Treat Autoimmune Diseases
1/3/2022
Kyverna Therapeutics today announced that the company has entered into exclusive, worldwide licenses with the National Institutes of Health (NIH) for intellectual property related to a novel clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties uniquely suited for use in autoimmune diseases.
-
This California biotech just bagged another partner for its endeavor to cure autoimmune disease with cell therapy.
-
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer
9/15/2021
Kyverna Therapeutics, Inc., today announced the appointment of Ian Clark as chair of the company's board of directors and the appointment of Karen Walker as Chief Technology Officer (CTO).
-
Kyverna Therapeutics Announces the Appointment of James Chung, M.D., Ph.D., as Chief Medical Officer
4/13/2021
Dr. Chung brings nearly 20 years' experience as a leader in autoimmune disease drug development with expertise in rheumatology, autoimmunity, and immunology Company also names world's leading immunology experts to Scientific Advisory Board
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.